Stock CYBN CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cybin Inc.

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		After market 06:30:14 pm
0.35 USD +1.16% Intraday chart for Cybin Inc. 0.346 -1.14%
Apr. 17 Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Apr. 16 Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment MT

Valuation

Fiscal Period: Maart 2021 2022 2023 2024 2025 2026
Capitalization 1 205.5 177.2 102.4 364.2 - -
Enterprise Value (EV) 1 141.4 123.5 85.8 193.8 238.4 186.3
P/E ratio -4.1 x -2.55 x -2 x -2.03 x -3.27 x -4.79 x
Yield - - - - - -
Capitalization / Revenue 238 x - - - - -
EV / Revenue 164 x - - - - -
EV / EBITDA -7.38 x -2.71 x -1.84 x -2.88 x -4.17 x -2.74 x
EV / FCF -7.38 x -2.73 x -1.8 x -3.19 x -4.16 x -2.52 x
FCF Yield -13.5% -36.7% -55.4% -31.4% -24% -39.6%
Price to Book 1.52 x 2.24 x 2 x 0.83 x 2 x 1.65 x
Nbr of stocks (in thousands) 156,782 173,458 196,913 760,053 - -
Reference price 2 1.310 1.021 0.5202 0.4791 0.4791 0.4791
Announcement Date 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - 0.864 - - - - -
EBITDA 1 - -19.17 -45.64 -46.58 -67.35 -57.15 -67.95
EBIT 1 - -32.28 -63.84 -51.52 -68.91 -67.88 -79.36
Operating Margin - -3,736.11% - - - - -
Earnings before Tax (EBT) 1 - -32.22 -67.63 -47.49 -74.45 -65.89 -68.45
Net income 1 -0.8098 -32.22 -67.63 -47.49 -74.32 -65.89 -80.48
Net margin - -3,729.17% - - - - -
EPS 2 - -0.3200 -0.4000 -0.2600 -0.2360 -0.1467 -0.1000
Free Cash Flow 1 - -19.16 -45.31 -47.57 -60.75 -57.26 -73.84
FCF margin - -2,217.82% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 11/9/20 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 - - - - - - - - - - - - - - -
EBITDA 1 -11.61 -11.95 -12.95 -11.19 -11.2 -11.04 -13.15 -12.64 -13.84 -26.88 -13.95 -13.8 -13.9 -14.2 -14.3
EBIT 1 -17.11 -16.46 -16.34 -13.4 -12.33 -12.09 -13.7 -12.71 -13.91 -27.02 -17.99 -14 -14.1 -14.4 -14.5
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -17.61 -17.21 -18.1 -13.06 -9.973 -10.74 -13.72 -14.51 -11.89 -30.33 -17.73 -12.5 -12.7 -13.1 -13.3
Net income 1 -17.61 -17.21 -18.1 -13.06 -10 -10.74 -13.72 -14.51 -11.89 -30.33 -18.24 -12.5 -12.7 -13.1 -13.3
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.1100 -0.1000 -0.1000 -0.0700 -0.0600 -0.0600 -0.0700 -0.0700 -0.0500 -0.0900 -0.0440 -0.0100 -0.0100 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 2/10/22 6/22/22 8/8/22 11/14/22 2/14/23 6/27/23 8/14/23 11/14/23 2/14/24 - - - - -
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 64 53.6 16.6 170 126 178
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -19.2 -45.3 -47.6 -60.8 -57.3 -73.8
ROE (net income / shareholders' equity) - -73.6% -79.2% -76.4% -46.4% -22.4% -26.3%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 0.8600 0.4600 0.2600 0.5800 0.2400 0.2900
Cash Flow per Share 2 - -0.1900 -0.2700 -0.2600 -0.1400 -0.0500 -0.0500
Capex 1 - 0.14 0.11 0.14 0.05 4.01 7.85
Capex / Sales - 15.62% - - - - -
Announcement Date 11/9/20 6/28/21 6/22/22 6/27/23 - - -
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.4791 CAD
Average target price
6.568 CAD
Spread / Average Target
+1,270.73%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CYBIN INC. Stock Cybin Inc.
-14.63% 266M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. Financials Cybin Inc.